Alcon에 대한 매도 수량은 투자자에게 Alcon의 주식 하락에 베팅하는 정도를 알려줍니다. 매도 수량 데이터는 2주마다 업데이트됩니다.

Alcon (NYSE:ALC) 주식, 공매도 수량 보고

Alcon

Alcon is one of the leading visioncare companies in the world. Following nine years as a Novartis subsidiary, it was spun off as a public company in April 2019. Alcon operates in two segments: visioncare and surgical. Visioncare comprises contact lenses, lenscare solutions, and a suite of ocular health products. With brands like Dailies, Total1, and Air Optix, Alcon controls one fourth of the U.S. contact lens market. Surgical comprises intraocular lenses, ophthalmic surgical equipment, and consumables used during surgeries. Its main products include Centurion, a phacoemulsification device used during cataract surgeries, and a portfolio of IOLs including PanOptix and Vivity. Alcon has one of the largest installed bases of eye surgical equipment in the world.

FLNT

PANW

화요일 오전 (현지 시간 기준) 미국 주식 선물이 약간 높게 거래되면서 오늘 투자자의 관심을 끌 수 있는 일부 주식은 다음과 같다: 월스트리트는 로우스(NYSE:LOW)가 개장 전 240억 1천만 달러의 매출과 주당 3.99달러의 분기 이익을 보고할 것으로 예상하고 있다. 벤징가 프로(Benzinga Pro)의 데이터에 따르면 로우스의 주가는 시간외 거래에서 0.2% 하락한 242.70달러를 기록했다.

화요일 주목해야 할 주식: 로우스, 알콘, 팔로알토 네트웍스 그리고 2종목

Equities

Large Cap

News

Movers

CRBG

DELL

MNDY

MSTR

ONON

PODD

SMCI

지난주 이들 대형주들은 최고의 성과를 거두었다. 그것들이 당신의 포트폴리오에 있나요? 마이크로스트레티지(NASDAQ:MSTR)의 주가가 비트코인 가격 상승 이후 30.10% 상승했다. 먼데이닷컴(NASDAQ:MNDY)의 주가는 예상보다 나은 1분기 재무 결과와 예상보다 높은 2분기 FY24 매출 지침에 따라 주가는 25.97% 상승했다. 몇몇 분석가들은 이 회사의 목표 가격을 높였다.

지난주 최고의 성과를 보인 마이크로스트레티지를 포함한 10개의 대형주 (5월 12일-18일)

Alcon Inc

Alternus Clean Energy, Inc. - Class A Common Stock

Alternus Clean Energy Inc

ALLIANCE INTL EDCATN LSNG by ALLIANCE INTL EDUCATION LEASING HLDGS LTD.

Alliance International Education Leasing Holdings Ltd

ALTECH CORP KANAGAWA by ALTECH CORP KANAGAWA

Altech Corp

ATLANTIC CNTRL ENTRPR LTD by Atlantic Central Enterprise Ltd.

Atlantic Central Enterprises Ltd

Alico Inc

ALCHIP TECHNOLOGS LTD TWD by ALCHIP TECHNOLOGIES LIMITED

Alchip Technologies Ltd

Alpha Copper Corp Ordinary Shares

Alpha Copper Corp

Alchemix - United States Dollar

Alchemy Investments Acquisition Corp 1 - Class A Ordinary Shares

Alchemy Investments Acquisition Corp 1

Alchemy Investments Acquisition Corp 1 - Units

Alchemy Investments Acquisition Corp 1 - Warrants

Top Wall Street analysts changed their outlook on these top names. For a complete view of all analyst rating changes, including upgrades and downgrades, please see our <a href="https://www.benzinga.com/analyst-stock-ratings">analyst ratings page</a>.
<ul>
<li>Baird raised the price target for CyberArk Software Ltd. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CYBR#NASDAQ">CYBR</a>) from $355 to $370. Baird analyst Shrenik Kothari maintained an Outperform rating. CyberArk Software shares closed at $319.16 on Monday. See how other analysts view this stock.</li>
<li>Mizuho raised the price target for Rubrik, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/RBRK#NYSE">RBRK</a>) from $75 to $82. Mizuho analyst Gregg Moskowitz maintained an Outperform rating. Rubrik shares closed at $75.51 on Monday. <a href="https://www.benzinga.com/quote/RBRK/analyst-ratings">See how other analysts view this stock.</a></li>
<li>Deutsche Bank boosted the price target for Planet Labs PBC (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/PL#NYSE">PL</a>) from $4 to $4.5. Deutsche Bank analyst Edison Yu maintained a Buy rating. Planet Labs shares closed at $4.33 on Monday. <a href="https://www.benzinga.com/quote/PL/analyst-ratings">See how other analysts view this stock</a>.</li>
<li>B of A Securities cut Knight-Swift Transportation Holdings Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/KNX#NYSE">KNX</a>) price target from $64 to $61. B of A Securities analyst Ken Hoexter maintained a Buy rating. Knight-Swift Transportation shares settled at $54.92 on Monday. <a href="https://www.benzinga.com/quote/KNX/analyst-ratings">See how other analysts view this stock</a>.</li>
<li>BMO Capital raised Ecolab Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ECL#NYSE">ECL</a>) price target from $279 to $290. BMO Capital analyst John McNulty upgraded the stock from Market Perform to Outperform. Ecolab shares closed at $248.40 on Monday. <a href="https://www.benzinga.com/quote/ECL/analyst-ratings">See how other analysts view this stock.</a></li>
<li>Mizuho boosted Tesla, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TSLA#NASDAQ">TSLA</a>) price target from $230 to $515. Mizuho analyst Vijay Rakesh upgraded the stock from Neutral to Outperform. Tesla shares closed at $463.02 on Monday.  <a href="https://www.benzinga.com/quote/TSLA/analyst-ratings">See how other analysts view this stock</a>.</li>
<li>Goldman Sachs cut Enphase Energy, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ENPH#NASDAQ">ENPH</a>) price target from $145 to $121. Goldman Sachs analyst Brian Lee maintained a Buy rating. Enphase Energy shares closed at $71.62 on Monday. See how other analysts view this stock.</li>
<li>Needham raised the price target for Alcon Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ALC#NYSE">ALC</a>) from $103 to $108. Needham analyst David Saxon maintained a Buy rating. Alcon shares settled at $83.87 on Monday. <a href="https://www.benzinga.com/quote/ALC/analyst-ratings">See how other analysts view this stock</a>.</li>
<li>Morgan Stanley raised Quest Diagnostics Incorporated (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/DGX#NYSE">DGX</a>) price target from $145 to $172. Morgan Stanley analyst Erin Wright upgraded the stock from Equal-Weight to Overweight. Quest Diagnostics shares closed at $152.65 on Monday. <a href="https://www.benzinga.com/quote/DGX/analyst-ratings">See how other analysts view this stock</a>.</li>
<li>Jefferies slashed Frontline plc (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/FRO#NYSE">FRO</a>) price target from $26 to $20. Jefferies analyst Omar Nokta maintained a Buy rating. Frontline shares closed at $13.81 on Monday. <a href="https://www.benzinga.com/quote/FRO/analyst-ratings">See how other analysts view this stock</a>.</li>
</ul>
Considering buying TSLA stock? Here&#8217;s what analysts think: 
<figure class="wp-block-image size-large is-resized"><img loading="lazy" decoding="async" width="1024" height="579" src="https://editorial-assets.benzinga.com/wp-content/uploads/2024/12/17082059/image-148-1024x579.png" alt="" class="wp-image-695772" style="width:605px;height:auto" srcset="https://editorial-assets.benzinga.com/wp-content/uploads/2024/12/17082059/image-148-1024x579.png 1024w,https://editorial-assets.benzinga.com/wp-content/uploads/2024/12/17082059/image-148-300x170.png 300w,https://editorial-assets.benzinga.com/wp-content/uploads/2024/12/17082059/image-148-768x434.png 768w,https://editorial-assets.benzinga.com/wp-content/uploads/2024/12/17082059/image-148.png 1136w" sizes="(max-width: 1024px) 100vw, 1024px" /></figure>
Read This Next:<a href="https://www.benzinga.com/news/earnings/24/12/42507875/how-to-earn-500-a-month-from-worthington-enterprises-stock-ahead-of-q2-earnings"> </a>
<ul>
<li><a href="https://www.benzinga.com/news/earnings/24/12/42507875/how-to-earn-500-a-month-from-worthington-enterprises-stock-ahead-of-q2-earnings">How To Earn $500 A Month From Worthington Enterprises Stock Ahead Of Q2 Earnings</a></li>
</ul>

Price Target

Pre-Market Outlook

Markets

Analyst Ratings

Trading Ideas

CYBR

ENPH

RBRK

TSLA

Tesla To Rally More Than 11%? Here Are 10 Top Analyst Forecasts For Tuesday

Needham analyst David Saxon maintains Alcon (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ALC#NYSE">ALC</a>) with a Buy and raises the price target from $103 to $108.

Needham Maintains Buy on Alcon, Raises Price Target to $108

Needham analyst David Saxon maintains Alcon (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ALC#NYSE">ALC</a>) with a Buy and lowers the price target from $107 to $103.

Needham Maintains Buy on Alcon, Lowers Price Target to $103

Needham analyst David Saxon reiterates Alcon (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ALC#NYSE">ALC</a>) with a Buy and maintains $107 price target.

Reiteration

Needham Reiterates Buy on Alcon, Maintains $107 Price Target

WIIM

Alcon shares are trading lower after the company reported worse-than-expected Q3 adjusted EPS results, issued FY24 core diluted EPS guidance below estimates, and cut its FY24 net sales guidance.

2024 outlook
The Company updated its 2024 outlook as per the table below.
<figure class="table"> 
<table>
<tbody>
<tr>
<td colspan="1" rowspan="1">2024 outlook4</td>
<td colspan="1" rowspan="1">as of February</td>
<td colspan="1" rowspan="1">as of May</td>
<td colspan="1" rowspan="1">as of August</td>
<td colspan="1" rowspan="1">as of November</td>
<td colspan="1" rowspan="1">Comments</td>
</tr>
<tr>
<td colspan="1" rowspan="1">Net sales (USD)</td>
<td colspan="1" rowspan="1">$9.9 to $10.1 billion</td>
<td colspan="1" rowspan="1">$9.9 to $10.1 billion</td>
<td colspan="1" rowspan="1">$9.9 to $10.1 billion</td>
<td colspan="1" rowspan="1">$9.8 to $9.9 billion</td>
<td colspan="1" rowspan="1">Updated</td>
</tr>
<tr>
<td colspan="1" rowspan="1">
Change vs. prior year (cc)1
(non-IFRS measure)
</td>
<td colspan="1" rowspan="1">+6% to +8%</td>
<td colspan="1" rowspan="1">+7% to +9%</td>
<td colspan="1" rowspan="1">+7% to +9%</td>
<td colspan="1" rowspan="1">+6% to +7%</td>
<td colspan="1" rowspan="1">Updated</td>
</tr>
<tr>
<td colspan="1" rowspan="1">
Core operating margin2
(non-IFRS measure)
</td>
<td colspan="1" rowspan="1">20.5% to 21.5%</td>
<td colspan="1" rowspan="1">20.5% to 21.5%</td>
<td colspan="1" rowspan="1">20.5% to 21.5%</td>
<td colspan="1" rowspan="1">20.5% to 21%</td>
<td colspan="1" rowspan="1">Tightened range</td>
</tr>
<tr>
<td colspan="1" rowspan="1">
Interest expense and
Other financial income &amp; expense
</td>
<td colspan="1" rowspan="1">$190 to $210 million</td>
<td colspan="1" rowspan="1">$180 to $200 million</td>
<td colspan="1" rowspan="1">$160 to $180 million</td>
<td colspan="1" rowspan="1">$155 to $165 million</td>
<td colspan="1" rowspan="1">Updated</td>
</tr>
<tr>
<td colspan="1" rowspan="1">
Core effective tax rate5
(non-IFRS measure)
</td>
<td colspan="1" rowspan="1">~20%</td>
<td colspan="1" rowspan="1">~20%</td>
<td colspan="1" rowspan="1">~20%</td>
<td colspan="1" rowspan="1">~19%</td>
<td colspan="1" rowspan="1">Updated</td>
</tr>
<tr>
<td colspan="1" rowspan="1">
Core diluted EPS2
(non-IFRS measure)
</td>
<td colspan="1" rowspan="1">$3.00 to $3.10</td>
<td colspan="1" rowspan="1">$3.00 to $3.10</td>
<td colspan="1" rowspan="1">$3.00 to $3.10</td>
<td colspan="1" rowspan="1">$3.00 to $3.05</td>
<td colspan="1" rowspan="1">Tightened range</td>
</tr>
<tr>
<td colspan="1" rowspan="1">
Change vs. prior year (cc)1
(non-IFRS measure)
</td>
<td colspan="1" rowspan="1">+13% to +16%</td>
<td colspan="1" rowspan="1">+15% to +18%</td>
<td colspan="1" rowspan="1">+15% to +18%</td>
<td colspan="1" rowspan="1">+15% to +17%</td>
<td colspan="1" rowspan="1">Tightened range</td>
</tr>
</tbody>
</table>
</figure>
This outlook assumes the following:
<ul>
<li>Aggregated markets grow in line with recent quarters;</li>
<li>Exchange rates as of the end of October 2024 prevail through year-end;</li>
<li>Approximately 498 million weighted-averaged diluted shares.</li>
</ul>
<figure class="table"> 
<table>
<tbody>
<tr>
<td colspan="1" rowspan="1">4.</td>
<td colspan="1" rowspan="1">The forward-looking guidance included in this press release cannot be reconciled to the comparable IFRS measures without unreasonable effort, because we are not able to predict with reasonable certainty the ultimate amount or nature of exceptional items in the fiscal year. Refer to the 'Footnotes' section for additional information.</td>
</tr>
<tr>
<td colspan="1" rowspan="1">5.</td>
<td colspan="1" rowspan="1">Core effective tax rate, a non-IFRS measure, is the applicable annual tax rate on core taxable income. Refer to the 'Footnotes' section for additional information.</td>
</tr>
</tbody>
</table>
</figure>
 &nbsp;

Guidance

Alcon Updates FY24 Core Diluted EPS From $3.00-$3.10 To $3.00-$3.05 Vs $3.06 Est.; Net Sales From $9.9B-$10.1B To $9.8B-$9.9B Vs $9.93B Est.

Alcon (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ALC#NYSE">ALC</a>) reported quarterly earnings of $0.81 per share which beat the analyst consensus estimate of $0.74 by 9.46 percent. This is a 22.73 percent increase over earnings of $0.66 per share from the same period last year. The company reported quarterly sales of $2.43 billion which missed the analyst consensus estimate of $2.46 billion by 1.10 percent. This is a 5.64 percent increase over sales of $2.30 billion the same period last year.

Earnings

Alcon Q3 Adj EPS $0.81 Beats $0.74 Estimate, Sales $2.43B Miss $2.46B Estimate

ABOS

ABSI

ACNT

ACTG

AENT

AGEN

AIOT

AIRG

ALIT

ALTG

AMBC

AMPS

AMTX

APEI

AREB

ARIS

ARMN

ATRA

AUTL

Avadel Pharmaceuticals plc - American Depositary Shares each representing one Ordinary Share

AVDL

AXSM

AZTA

BHIL

BLDE

BLFS

BLTE

The Beachbody Company, Inc. Class A Common Stock

BODI

BRTX

BTMD

BTTR

BWAY

BXSL

BZFD

CAMT

CART

CATX

CAVA

CBAT

CBLL

CCLD

CGEN

CHGG

CHMI

CLSD

CNNE

CRNX

CRON

CRVS

CRWS

CVAC

CXAI

DAVA

DAVE

DRCT

DYAI

EARN

EGAN

ELMD

ETON

EVCM

EVGO

EYEN

FENG

FGEN

FIHL

FLNG

FOUR

FTCI

GENI

GENK

GMGI

GOVX

GRAL

GRDN

GROV

GRPN

GRVY

Earnings Scheduled For November 12, 2024

Keybanc analyst Brett Fishbin maintains Alcon (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ALC#NYSE">ALC</a>) with a Overweight and raises the price target from $103 to $107.

Keybanc Maintains Overweight on Alcon, Raises Price Target to $107

BTIG analyst Ryan Zimmerman maintains Alcon (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ALC#NYSE">ALC</a>) with a Buy and raises the price target from $104 to $106.

BTIG Maintains Buy on Alcon, Raises Price Target to $106

Redburn Atlantic analyst Issie Kirby upgrades Alcon (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ALC#NYSE">ALC</a>) from Sell to Neutral.

Upgrades

Redburn Atlantic Upgrades Alcon to Neutral

Top Wall Street analysts changed their outlook on these top names. For a complete view of all analyst rating changes, including upgrades and downgrades, please see our <a href="https://www.benzinga.com/analyst-stock-ratings">analyst ratings page.</a>
<ul>
<li>Needham raised the price target for Docebo Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/DCBO#NASDAQ">DCBO</a>) from $45 to $50. Needham analyst Ryan MacDonald maintained a Buy rating. Docebo shares fell 0.9% to close at $41.29 on Wednesday. <a href="https://www.benzinga.com/quote/DCBO/analyst-ratings">See how other analysts view this stock.</a></li>
<li>Ascendiant Capital increased the price target for RenovoRx, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/RNXT#NASDAQ">RNXT</a>) from $8 to $8.25.. Ascendiant Capital analyst Edward Woo maintained a Buy rating. RenovoRx shares rose 0.1% to close at $1.05 on Wednesday. <a href="https://www.benzinga.com/quote/rnxt/analyst-ratings">See how other analysts view this stock.</a></li>
<li>HC Wainwright &amp; Co. raised Instil Bio, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TIL#NASDAQ">TIL</a>) price target from $25 to $40. HC Wainwright &amp; Co. analyst Mitchell Kapoor maintained a Buy rating. Instil Bio shares gained 20.6% to close at $29.65 on Wednesday. <a href="https://www.benzinga.com/quote/til/analyst-ratings">See how other analysts view this stock.</a></li>
<li>Baird cut Domino&#8217;s Pizza, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/DPZ#NYSE">DPZ</a>) price target from $580 to $535. Baird analyst David Tarantino maintained an Outperform rating. Domino&#8217;s shares fell 2.1% to close at $407.97 on Wednesday. <a href="https://www.benzinga.com/quote/dpz/analyst-ratings">See how other analysts view this stock.</a></li>
<li>Piper Sandler raised the price target for Exact Sciences Corporation (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/EXAS#NASDAQ">EXAS</a>) from $75 to $85. Piper Sandler analyst David Westenberg maintained an Overweight rating. Exact Sciences shares gained 9.8% to close at $64.12 on Wednesday. <a href="https://www.benzinga.com/quote/exas/analyst-ratings">See how other analysts view this stock.</a></li>
<li>Truist Securities boosted Aramark (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ARMK#NYSE">ARMK</a>) price target from $37 to $42. Truist Securities analyst Jasper Bibb maintained a Buy rating. Aramark shares gained 0.5% to close at $37.99 on Wednesday. <a href="https://www.benzinga.com/quote/armk/analyst-ratings">See how other analysts view this stock.</a></li>
<li>Morgan Stanley increased TransUnion (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/TRU#NYSE">TRU</a>) price target from $96 to $103. Morgan Stanley analyst Toni Kaplan maintained an Overweight rating. TransUnion shares rose 0.2% to close at $96.44 on Wednesday. <a href="https://www.benzinga.com/quote/tru/analyst-ratings">See how other analysts view this stock.</a></li>
<li>Mizuho cut the price target for Advance Auto Parts, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/AAP#NYSE">AAP</a>) from $45 to $38. Mizuho analyst David Bellinger maintained a Neutral rating. Advance Auto Parts shares rose 0.6% to close at $38.77 on Wednesday. <a href="https://www.benzinga.com/quote/aap/analyst-ratings">See how other analysts view this stock.</a></li>
<li>Mizuho boosted American Tower Corporation (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/AMT#NYSE">AMT</a>) price target from $205 to $221. Mizuho analyst Vikram Malhorta maintained a Neutral rating. American Tower shares fell 1.6% to close at $238.97 on Wednesday. <a href="https://www.benzinga.com/quote/amt/analyst-ratings">See how other analysts view this stock.</a></li>
<li>BTIG raised Alcon Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ALC#NYSE">ALC</a>) price target from $98 to $104. BTIG analyst Ryan Zimmerman maintained a Buy rating. Alcon shares rose 0.1% to close at $98.22 on Wednesday. <a href="https://www.benzinga.com/quote/dpz/analyst-ratings">See how other analysts view this stock.</a></li>
</ul>
Considering buying EXAS stock? Here&#8217;s what analysts think: 
<figure class="wp-block-image size-large is-resized"><img loading="lazy" decoding="async" width="1024" height="517" src="https://editorial-assets.benzinga.com/wp-content/uploads/2024/09/12075315/image-100-1024x517.png" alt="" class="wp-image-544353" style="width:612px;height:auto" srcset="https://editorial-assets.benzinga.com/wp-content/uploads/2024/09/12075315/image-100-1024x517.png 1024w,https://editorial-assets.benzinga.com/wp-content/uploads/2024/09/12075315/image-100-300x151.png 300w,https://editorial-assets.benzinga.com/wp-content/uploads/2024/09/12075315/image-100-768x387.png 768w,https://editorial-assets.benzinga.com/wp-content/uploads/2024/09/12075315/image-100.png 1342w" sizes="(max-width: 1024px) 100vw, 1024px" /></figure>
Read Next: 
<ul>
<li><a href="https://www.benzinga.com/top-stories/24/09/40813043/jim-cramer-not-the-time-to-own-oil-when-asked-about-exxon-mobil-says-ibm-is-performing-well">Jim Cramer: &#8216;Not The Time To Own Oil,&#8217; When Asked About Exxon Mobil; Says IBM Is &#8216;Performing Well&#8217;</a></li>
</ul>

ARMK

DCBO

EXAS

RNXT

Exact Sciences To Rally Around 33%? Here Are 10 Top Analyst Forecasts For Thursday

BTIG analyst Ryan Zimmerman maintains Alcon (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ALC#NYSE">ALC</a>) with a Buy and raises the price target from $98 to $104.

BTIG Maintains Buy on Alcon, Raises Price Target to $104

RBC Capital analyst Jack Reynolds-Clark upgrades Alcon (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ALC#NYSE">ALC</a>) from Sector Perform to Outperform.

RBC Capital Upgrades Alcon to Outperform

Alcon Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ALC#NYSE">ALC</a>) reported mixed second-quarter results, <a href="https://www.benzinga.com/quote/ALC/earnings">after the closing bell on Tuesday.</a>
Alcon reported quarterly earnings of 74 cents per share which beat the analyst consensus estimate of 73 cents per share. The company reported quarterly sales of $2.48 billion which missed the analyst consensus estimate of $2.52 billion.
&#8220;We are pleased with our solid second-quarter results, which were driven by robust demand for our innovative products, our balanced geographic footprint and strong execution by our team. These factors contributed to another quarter of sales and earnings growth and robust cash generation,&#8221; said David J. Endicott, Alcon&#8217;s Chief Executive Officer. &#8220;As we look to the second half of the year, our focus will be on preparing for product launches that will position us well for our next phase of growth in 2025 and beyond.&#8221;
Alcon said it sees FY24 earnings of $3.00 to $3.10 per share on revenue of $9.9 billion to $10.1 billion.
Alcon shares gained 0.9% to trade at $95.50 on Thursday.
These analysts made changes to their price targets on Alcon following earnings announcement.
<ul>
<li><a href="https://www.benzinga.com/analyst-stock-ratings/analyst/5e4d0a4aece4e600011f1fdc/david-saxon">Needham analyst David Saxon</a> maintained Alcon with a Buy and raised the price target from $101 to $107.</li>
<li><a href="https://www.benzinga.com/analyst-stock-ratings/analyst/586bc4bd351b9b0001ab7364/jeff-johnson">Baird analyst Jeff Johnson</a> maintained the stock with an Outperform and raised the price target from $104 to $110.</li>
<li>BTIG analyst Ryan Zimmerman maintained Alcon with a Buy, while increasing the price target from $96 to $98.</li>
<li>Oppenheimer analyst <a href="https://www.benzinga.com/analyst-stock-ratings/analyst/5e4d0a4aece4e600011f1fdc/david-saxon">Steven Lichtman</a> maintained the stock with an Outperform and raised the price target from $103 to $110.</li>
<li><a href="https://www.benzinga.com/analyst-stock-ratings/analyst/584eee82ee7bf60001abdc10/larry-biegelsen">Wells Fargo analyst Larry Biegelsen</a> maintained Alcon with an Overweight rating, while raising the price target from $94 to $105.</li>
</ul>
Considering buying ALC stock? Here&#8217;s what analysts think: 
<figure class="wp-block-image size-large is-resized"><img loading="lazy" decoding="async" width="1024" height="524" src="https://editorial-assets.benzinga.com/wp-content/uploads/2024/08/22120010/image-200-1024x524.png" alt="" class="wp-image-509074" style="width:573px;height:auto" srcset="https://editorial-assets.benzinga.com/wp-content/uploads/2024/08/22120010/image-200-1024x524.png 1024w,https://editorial-assets.benzinga.com/wp-content/uploads/2024/08/22120010/image-200-300x153.png 300w,https://editorial-assets.benzinga.com/wp-content/uploads/2024/08/22120010/image-200-768x393.png 768w,https://editorial-assets.benzinga.com/wp-content/uploads/2024/08/22120010/image-200.png 1302w" sizes="(max-width: 1024px) 100vw, 1024px" /></figure>

Alcon Analysts Increase Their Forecasts After Q2 Results

Wells Fargo analyst Larry Biegelsen maintains Alcon (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ALC#NYSE">ALC</a>) with a Overweight and raises the price target from $94 to $105.

Wells Fargo Maintains Overweight on Alcon, Raises Price Target to $105

Oppenheimer analyst Steven Lichtman maintains Alcon (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ALC#NYSE">ALC</a>) with a Outperform and raises the price target from $103 to $110.

Oppenheimer Maintains Outperform on Alcon, Raises Price Target to $110

BTIG analyst Ryan Zimmerman maintains Alcon (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ALC#NYSE">ALC</a>) with a Buy and raises the price target from $96 to $98.

BTIG Maintains Buy on Alcon, Raises Price Target to $98

Baird analyst Jeff Johnson maintains Alcon (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ALC#NYSE">ALC</a>) with a Outperform and raises the price target from $104 to $110.

Baird Maintains Outperform on Alcon, Raises Price Target to $110

Needham analyst David Saxon maintains Alcon (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ALC#NYSE">ALC</a>) with a Buy and raises the price target from $101 to $107.

Needham Maintains Buy on Alcon, Raises Price Target to $107

Impax Global Opportunities Fund Q3 2024 Commentary

UBS's global equity focus list: stocks within health technology

Stifel downgraded RxSight (RXST) to Hold from Buy with a price target of $40, down from $65. The firm's latest deep-dive survey of surgeons leads t...

RxSight downgraded to Hold from Buy at Stifel

RxSight cut to hold at Stifel on competition concerns

<a href="https://investorplace.com">InvestorPlace - Stock Market News, Stock Advice &amp; Trading Tips</a>
Alcon (NYSE:<a href="https://investorplace.com/stock-quotes/alc-stock-quote/">ALC</a>) just reported results for the second quarter of 2024.<ul><li>Alcon reported earnings per share of 74 cents. This was above the analyst estimate for EPS of 73 cents.</li><li>The company reported revenue of $2.48 billion.</li><li>This was 1.51% worse than the analyst estimate for revenue of $2.52 billion.</li></ul><div>InvestorPlace Earnings is a project that leverages data from <a href="https://www.tradesmith.com">TradeSmith</a> to automate coverage of quarterly earnings reports. InvestorPlace Earnings distills key takeaways including earnings per share and revenue, as well as how a company stacks up to analyst estimates. These articles are published without human intervention, allowing us to inform our readers of the latest figures as quickly as possible. To report any concerns or inaccuracies, please contact us at <a href="mailto:editor@investorplace.com">editor@investorplace.com</a>.</div>	
	The post <a href="https://investorplace.com/earning-results/2024/08/alc-stock-earnings-alcon-for-q2-of-2024/">ALC Stock Earnings: Alcon Beats EPS, Misses Revenue for Q2 2024</a> appeared first on <a href="https://investorplace.com">InvestorPlace</a>.

ALC Stock Earnings: Alcon Beats EPS, Misses Revenue for Q2 2024

Stifel Nicolaus analyst Thomas Stephan maintained a Buy rating on Alcon (ALC – Research Report) yesterday. The company's shares closed last Wednesd...

Stifel Nicolaus Remains a Buy on Alcon (ALC)

Redburn Atlantic analyst Issie Kirby upgraded Alcon (ALC) to Buy from Neutral with a price target of CHF 93, up from CHF 80. The firm views fiscal ...

Comments

Alcon

매도 수량

Alcon (NYSE:ALC) 주식, 공매도 수량 보고

뉴스

파트너 / 기고자

벤징가 글로벌